| Category | Details |
|---|---|
| Company Name | Toothsi (MakeO) |
| Founded Year | 2018 |
| industry / Sector | HealthTech / Dental Technology / Digital Healthcare / MedTech |
| Headquarters | Mumbai, Maharashtra, India |
| Company Revenue | Estimated ₹350–600 crore annual operating revenue (FY2025 estimate) |
| Valuation | Estimated US$400–600 million (based on funding rounds and market estimates; official current valuation has not been publicly disclosed) |
| Founders | Dr. Arpi Mehta, Dr. Ashwin Bhadri, and Rohit Chawla |
| Company Type | Private, Venture-backed HealthTech Company |
| Products / Platforms | Clear Aligners, Invisible Teeth Braces, Smile Makeover Solutions, Digital Orthodontic Consultations, 3D Smile Scan, AI-Based Treatment Planning, Teeth Whitening, Oral Care Products, MakeO App, At-Home Dental Assessment |
| Target Market | Teenagers, young professionals, adults seeking cosmetic dentistry, orthodontic patients, urban consumers, and individuals looking for convenient, technology-enabled dental care and smile correction |
| Market Role | One of India’s leading digital orthodontics companies, providing clear aligner treatments and technology-driven smile correction through a hybrid model of digital consultations and partner dental clinics |
| Unique Value | AI-assisted treatment planning, personalized clear aligners, at-home smile assessment, 3D digital scanning, partner orthodontist network, flexible payment plans, remote treatment monitoring, technology-enabled patient engagement, and convenient access to cosmetic dental care |
| Geographic Presence | Operates across major Indian metropolitan cities through an extensive network of partner dental clinics and digital consultation services, with continued expansion into new urban markets |
| Growth Snapshot | Toothsi has rapidly emerged as one of India’s leading digital smile correction brands by making orthodontic treatment more accessible and convenient through clear aligner technology. The company expanded its offerings under the MakeO brand into broader cosmetic and wellness services, strengthened its AI-driven treatment capabilities, partnered with hundreds of dental professionals, and attracted significant venture capital investment. By combining digital healthcare, personalized treatment plans, and advanced orthodontic technology, Toothsi continues to reshape India’s cosmetic dentistry market while strengthening its position in the growing digital smile correction industry. |
Toothsi Business Model: Transforming Orthodontic Care Through Digital Innovation.
Corporate Genesis and Company Overview
The contemporary healthcare landscape is undergoing a profound structural transformation, driven by the convergence of digital technology, direct-to-consumer (D2C) marketing, and clinical elective medicine. At the epicenter of this disruption within the Indian subcontinent is MakeO Healthcare Technologies Private Limited. Originally incorporated in 2018 in Mumbai, Maharashtra, under the name AMPA Orthodontics Private Ltd., the enterprise was conceptualized by a consortium of four practicing orthodontists. The founders identified a significant market friction: traditional metal braces, requiring frequent clinical visits and presenting a highly visible, often stigmatized aesthetic, acted as a major deterrent for older teenagers and adults seeking orthodontic correction.
To bridge this gap, the company launched its flagship brand, Toothsi, introducing an at-home, clear aligner delivery model engineered to democratize access to smile correction. Recognizing the cross-selling potential inherent in their rapidly expanding, aesthetic-conscious consumer base, the founders subsequently launched Skinnsi in 2021. Skinnsi pivoted the company’s operational logistics toward clinical cosmetology, offering dermatologist-backed services such as laser hair reduction and derma-facials directly to the consumer’s home or via dedicated clinics. In September 2022, recognizing the strategic imperative of a unified corporate identity, the dental and dermatological verticals were consolidated under the overarching umbrella brand “MakeO”. From its origins as a localized dental startup, MakeO has rapidly evolved into a pan-Asian clinical beauty and aesthetic platform, operating across more than 100 Indian cities and extending its operational footprint into the Gulf Cooperation Council (GCC) and broader Southeast Asian markets.
Executive Leadership and Management Governance
The structural integrity and strategic direction of any health-tech enterprise rely heavily on the clinical legitimacy of its leadership. Unlike numerous consumer startups founded purely by technology or marketing entrepreneurs, MakeO is distinctly doctor-led, a factor that fundamentally shapes its operational ethos, clinical protocols, and market positioning. The executive leadership team brings a combination of specialized medical expertise and corporate ambition.
The corporate hierarchy is spearheaded by Dr. Arpi Mehta, serving as Co-Founder and Chief Executive Officer. Holding a Master’s degree in Dental Surgery from the illustrious Nair Hospital Dental College, with advanced certification in lingual orthodontics from Paris and Geneva, Dr. Mehta transitioned from a successful private practice to driving MakeO’s overarching corporate strategy. Dr. Pravin Shetty, Co-Founder and Director, serves as the operational architect. As a pioneer in lingual orthodontics and the inventor of India’s first CAD/CAM-based customized 3D-lingual bracket system (Lingualmatrix), Dr. Shetty directs MakeO’s central operations. His purview includes the supervision of 3D virtual treatment planning, the massive aligner manufacturing laboratory, and advanced clinical research and development.
Quality control and clinical education are managed by Dr. Manjul Jain, Co-Founder and Director. A certified lingual orthodontist from Germany, Dr. Jain oversees the critical function of Quality Management Systems (QMS) for the digital lab and manages professional training frameworks for the company’s network of dental partners. Rounding out the founding team is Dr. Anirudha Kale, who brings 25 years of clinical expertise to his role in managing clinical marketing and spearheading strategic dental partnerships across the ecosystem.
The evolution of MakeO’s capitalization table is accurately reflected in its board composition. The transition from a bootstrapped entity to a heavily venture-backed enterprise has introduced significant institutional oversight. The board includes the four co-founders alongside institutional representatives, notably Dr. Prem Venkatalachalam Pavoor, a Senior Partner and Nominee Director representing Eight Roads Ventures, the company’s most prominent external stakeholder. This governance structure ensures rigorous financial oversight, although public disclosures regarding specific proxy structures, voting rights, or internal board dynamics remain closely guarded.
| Executive / Board Member | Title and Core Responsibility | Affiliation / Background |
| Dr. Arpi Atul Mehta | Co-Founder & CEO (Corporate Strategy & Vision) | MakeO / Nair Hospital Dental College |
| Dr. Pravin Shankar Shetty | Co-Founder & Director (Central Operations, Lab R&D) | MakeO / Inventor of Lingualmatrix |
| Dr. Manjul Mangilal Jain | Co-Founder & Director (QMS & Clinical Training) | MakeO / KLE Institute of Dental Sciences |
| Dr. Anirudha Shailesh Kale | Co-Founder & Director (Clinical Marketing & Partnerships) | MakeO / Founder of Simply Braces |
| Dr. Prem V. Pavoor | Nominee Director (Institutional Oversight) | Eight Roads Ventures |
Strategic Business Model
MakeO operates on a high-volume, vertically integrated direct-to-consumer (D2C) business model, which has recently been augmented by an expanding omnichannel physical clinic presence. This hybrid approach represents a critical evolution from the pure remote-care models that have historically faced severe clinical and regulatory failures globally. By controlling the entire value chain—from initial lead generation and 3D intraoral scanning to AI-driven treatment planning, proprietary manufacturing, and last-mile delivery—MakeO successfully bypasses traditional distribution intermediaries, thereby preserving gross margins.
The consumer journey initiates via aggressive digital marketing campaigns. Prospective patients are offered a choice: an at-home 3D intraoral scan conducted by a visiting certified technician, or an in-person consultation at one of MakeO’s 110+ physical “Experience Centers” or 2,000+ partner dental clinics nationwide. This initial touchpoint is heavily subsidized to drastically lower the barrier to entry. Upon capturing the digital impression, the data is transmitted to the central facility where orthodontists utilize AI software to generate a predictive, interactive “Virtual Smile Plan”. Once the patient approves the projected outcome and secures financing—often facilitated through accessible EMI options—the custom aligners are 3D-printed, thermoformed, and shipped directly to the consumer.
To accelerate geographic penetration into Tier-2 and Tier-3 cities without assuming the prohibitive capital expenditures associated with commercial real estate, MakeO has instituted a robust franchise model. The franchise architecture is designed to be asset-light for the parent company. Franchisees are required to invest approximately ₹10 to ₹15 lakhs, covering the initial franchise fee, infrastructure setup (₹5-8 lakhs), and initial operational capital. In return, MakeO provides established brand equity, centralized manufacturing, a continuous flow of digital leads, and comprehensive staff training. This methodology shifts localized operational risks to the franchisee while ensuring MakeO captures the highly profitable manufacturing and technological margins.
Comprehensive Products and Services Ecosystem
MakeO’s product portfolio is meticulously segmented into dental (Toothsi) and dermatological (Skinnsi) offerings, creating a unified clinical aesthetic platform that maximizes cross-selling opportunities and customer lifetime value.
The flagship Toothsi offering comprises US FDA 510(k)-cleared and ISO 13485-certified clear aligners. These transparent, removable thermoformed plastic trays apply continuous, gentle force to correct complex malocclusions, including crowding, spacing, open bites, crossbites, and forwardly placed teeth. Treatment duration is highly customized, typically ranging from 4 to 18 months, utilizing a sequenced series of aligners. Beyond active alignment, the Toothsi ecosystem encompasses pre-treatment and post-treatment adjunctive products. These include retainers (essential for preventing post-treatment relapse), high-intensity teeth whitening kits, and proprietary oral hygiene maintenance products like “Toothsi Foamy,” which is explicitly designed to clean aligners without causing abrasive damage to the thermoplastic material.
Pivoting from the success of at-home dental scans, the Skinnsi vertical applies the same rigorous operational logistics to clinical dermatology. The core services are designed to replicate clinic-level efficacy in a home environment or at dedicated experience centers. Skinnsi utilizes advanced quadruple-wavelength, ice-cool laser technology for permanent hair reduction, capable of treating various hair thicknesses across all skin types safely without thermal damage. The facial aesthetics division offers tool-based, zero-human-touch treatments. The premier offering is the Hydra Facial, a sophisticated 8-step process utilizing US FDA-approved hydradermabrasion technology, H2 therapy to extract free radicals, electroporation with Vitamin C serums, and lactic acid peels to combat pigmentation and aging. Additionally, Skinnsi has ventured into advanced trichology, providing Platelet-Rich Plasma (PRP) therapies, Exosome hair treatments, and Growth Factor Concentrate (GFC) therapy to address severe hair fall and scalp conditions.
| Vertical | Primary Product/Service | Mechanism & Technology | Average Cost / Pricing |
| Toothsi (Dental) | Clear Aligners | 3D-printed molds, thermoformed TPU plastic, continuous force application. | ₹52,999 to ₹1,30,000 |
| Toothsi (Dental) | Teeth Whitening & Care | Chemical whitening kits, aligner cleaning foams, electric toothbrushes. | Variable (FMCG pricing) |
| Skinnsi (Derma) | Laser Hair Reduction | Quadruple-wavelength laser with ice-cool technology for painless follicular targeting. | Package based (EMI available) |
| Skinnsi (Derma) | Advanced Hydra Facials | 8-step hydradermabrasion, H2 therapy, electroporation, lactic acid peeling. | ₹3,000 – ₹4,000 per session |
| Skinnsi (Trichology) | Hair Restoration Therapies | Platelet-Rich Plasma (PRP), Exosome treatments, Growth Factor Concentrate (GFC). | ₹5,000 – ₹6,000 per session |
Target Market and Consumer Demographics
The total addressable market (TAM) for clear aligners is experiencing a profound structural shift. Historically, orthodontic treatment was viewed primarily as an adolescent medical necessity. However, contemporary data indicates that approximately 30% of adults could benefit from orthodontic intervention. This demographic has transitioned adult orthodontics from a cyclical medical expenditure to a compounding, structural growth driver anchored in personal wellness and aesthetic enhancement.
MakeO strategically targets urban and semi-urban millennials and Gen-Z consumers. This cohort prioritizes discretion, convenience, and technology-enabled experiences. The removability of clear aligners during professional interactions, their near-invisibility in daily wear, and their compatibility with adult oral hygiene routines are attributes that traditional fixed appliances structurally cannot replicate. Projections indicate that the adult segment will completely dominate the clear aligner market, capturing an estimated 74.42% market share by 2026, driven by a post-pandemic prioritization of health and a sustained cultural emphasis on professional appearance. MakeO’s dual positioning in both smile correction and cosmetic dermatology perfectly encapsulates the demands of this demographic, allowing the company to acquire a customer for a dental alignment and subsequently retain them for a decade of ongoing skin and hair maintenance.
Market Position and Competitive Landscape
MakeO operates at the highly lucrative nexus of the clear aligner and aesthetic dermatology markets. The clear aligner market in India was valued at approximately $96 million in 2022 and is projected to expand at an aggressive Compound Annual Growth Rate (CAGR) of 34.07%, potentially reaching nearly $1 billion by 2030. Globally, the clear aligner market size was valued at USD 4.22 billion in 2025 and is projected to skyrocket to USD 13.29 billion by 2034.
Within this expanding ecosystem, the competitive landscape is rigidly stratified. The premium tier is unconditionally dominated by Align Technology (the manufacturer of Invisalign), which held a global market share of over 68.8% in 2025. Align Technology relies entirely on a B2B2C model, distributing exclusively through certified orthodontists rather than engaging directly with consumers. MakeO (Toothsi) positions itself aggressively as the market leader in the mid-market challenger tier. By pricing its aligners starting at ₹52,999—substantially lower than Invisalign’s ₹1,50,000 to ₹4,00,000 range—Toothsi captures the massive middle-class demographic priced out of premium care.
However, MakeO faces intense domestic competition from homegrown budget brands such as Snazzy, 32 Watts, Flash Orthodontics, and Illusion Aligners, which compete fiercely on price and localization. To defend its market position against budget competitors, MakeO relies on its superior clinical credentials, massive manufacturing scale, and the halo effect of high-profile celebrity endorsements.
Technology, Innovation, and Manufacturing Operations
MakeO’s competitive moat is deeply entrenched in its technological infrastructure, seamlessly bridging advanced artificial intelligence algorithms with industrial-scale additive manufacturing. The integration of AI into treatment planning represents a quantum leap in operational efficiency.
The clinical workflow begins with 3D laser scanning. A handheld optical wand projects a light source to capture millions of topographical data points within the oral cavity, eliminating the gag reflex associated with traditional alginate impressions and transmitting the digital model instantaneously to the laboratory. At the central planning facility, AI-powered platforms automate tooth segmentation, three-dimensional arch setup, and force vector prediction—tasks that historically required hours of skilled clinical technician input per case. This automation compresses the case initiation cycle, enabling orthodontists to present patients with projected treatment outcomes in near real-time.
MakeO’s physical operations are anchored by a massive 20,000 square foot manufacturing laboratory in Mumbai, representing the largest 3D aligner printing facility in India. The facility operates under rigorous ISO 13485 medical device quality management standards and is capable of outputting over 100,000 aligners monthly. The fabrication process is highly sophisticated. Patient-specific models are 3D printed using advanced light-force resins. Subsequently, high-grade, triple-layer thermoplastic polyurethane (TPU) sheets—imported from the United States, CE-certified, and strictly BPA/phthalate-free—are thermoformed over these models.
Crucially, MakeO has revolutionized the finishing process by integrating a futuristic robotic aligner trimming module, a first for an Indian aligner brand. This automation replaces error-prone manual trimming, ensuring the aligner perfectly follows the patient’s unique gingival margin with sub-millimeter precision. This technological upgrade drastically reduces soft-tissue irritation and enhances patient comfort. Final production stages include advanced laser marking for batch tracking, automated deburring to polish sharp edges, and stringent medical-grade sterilization.
Marketing Strategies and Customer Acquisition
Customer acquisition in the D2C healthcare space is notoriously expensive, requiring a delicate balance between brand building and performance marketing. MakeO’s marketing strategy has heavily disrupted the traditionally localized and relationship-based dental sector.
To overcome the initial skepticism associated with remote medical devices, MakeO partnered with specialized digital agencies, such as Inqnest, to execute comprehensive brand overhauls and integrated digital marketing campaigns. This involved deep Search Engine Optimization (SEO), targeting high-intent keywords, and optimizing product listings across e-commerce platforms like Amazon. A critical component of this strategy was the creation of interactive 2D and 3D assets that allowed consumers to virtually explore the products, resulting in a reported 72% increase in sales across e-commerce channels within six months of implementation.
At the macro-brand level, MakeO has invested heavily in celebrity influencer marketing to build instant credibility. The appointment of mega-celebrities like Virat Kohli and Anushka Sharma as brand ambassadors in 2022 signaled a massive capital deployment aimed at cementing Toothsi as an aspirational, household name. While this generated immense top-of-funnel awareness, the associated advertising and promotion costs ballooned 15.7x to ₹66.97 crore in FY22, significantly exacerbating the company’s cash burn. The strategic challenge for MakeO’s marketing division is transitioning from paid acquisition to organic, referral-based growth, leveraging their 300,000+ completed smiles to drive lower-cost patient acquisition.
Operations, Supply Chain, and Logistics
Efficient logistics directly dictate the speed, cost-effectiveness, and ultimate success of a distributed medical device business. MakeO’s supply chain is highly centralized, with the Mumbai laboratory serving as the solitary manufacturing hub.
The operational flow requires precise synchronization. Impression kits or 3D scanners must be deployed to the patient’s location via a network of field technicians. Once the data is processed, the physical aligners are dispatched through extensive delivery networks designed to ensure timely, temperature-controlled transit to prevent the thermoplastic from warping. MakeO mitigates logistical bottlenecks by forming strategic partnerships with over 2,200 dental professionals and orthodontists across India. This localized network not only aids in physical distribution but also provides emergency clinical support, ensuring patients have a physical touchpoint if remote monitoring proves insufficient. The recent acquisition of Zenyum further complicates and expands this supply chain, requiring MakeO to export its manufactured goods across a massive pan-Asian corridor spanning from the Middle East to Japan.
Customer Experience and Brand Loyalty
In elective healthcare, patient adherence and satisfaction are paramount. The clear aligner process requires strict patient compliance—wearing the trays for 20 to 22 hours daily. MakeO manages customer experience through an integrated digital ecosystem.
The “Toothsi Smile Journey App” acts as the central hub for patient interaction. The application allows users to upload images and videos of their dental progress, which are reviewed asynchronously by orthodontists, reducing the need for physical clinic visits. The app also tracks daily wear time, sends reminders for aligner changes, and facilitates instant scheduling for tele-consultations. This gamification and continuous digital hand-holding have yielded high customer satisfaction metrics, evidenced by over 12,000 Google reviews averaging 4.5+ stars. By offering comprehensive pre- and post-care instructions, including strict guidelines on maintenance (e.g., avoiding hot water, utilizing the specific Toothsi Foamy cleaner), the company actively manages expectations and minimizes treatment failure.
Company Culture and Workforce Dynamics
In stark contrast to its polished consumer-facing brand, internal metrics reveal significant friction regarding company culture. Analysis of employee feedback across platforms like Glassdoor and AmbitionBox paints a picture of a highly pressurized, volatile startup environment.
The company struggles with a composite culture rating of just 1.9 out of 5 stars. Employees frequently cite severe work-life balance issues, a lack of job security characterized by a “hire and fire” mentality, erratic changes in operational structure, and toxic behavior from mid-to-upper management. While junior corporate staff note that the fast-paced environment offers rapid learning opportunities, clinical professionals—including dental surgeons and skin therapists—have reported deep dissatisfaction. Complaints include inadequate compensation structures, delayed payments, and unachievable sales targets that incentivize unethical clinical practices.
This cultural volatility represents a severe latent risk. In clinical healthcare, the quality of service is entirely dependent on the morale, focus, and ethics of the frontline practitioner. High attrition rates among dermatologists and orthodontists directly threaten clinical outcomes. Furthermore, soaring Employee Stock Ownership Plan (ESOP) expenses—amounting to ₹21 crore in FY23—highlight the immense financial premium the company must pay in attempting to retain executive and engineering talent in a high-churn environment. Toothsi Business Model: Transforming Orthodontic Care Through Digital Innovation.
Financial Performance and Unit Economics
An analysis of MakeO’s consolidated financial filings reveals the classic trajectory of a late-stage venture capital-backed consumer startup: explosive hyper-growth fueled by massive cash burn, followed by a necessary, painful strategic pivot toward sustainable economics and loss reduction.
Between FY21 and FY22, MakeO achieved staggering growth, with operating revenue surging 5.3x from ₹14.6 crore to ₹78.45 crore. However, this growth came at a severe cost. Losses drastically outpaced revenue growth, ballooning 6.3x to ₹184.29 crore. By FY23, the scale doubled again to ₹168 crore, but expenses remained stubbornly high at ₹395 crore, resulting in a peak net loss of ₹220 crore. During this period, employee benefit expenses emerged as the largest cost center, growing 76.4% to ₹127 crore.
The fiscal year ending March 2024 (FY24) marked a vital stabilization phase. Operating revenue saw a modest stabilization at ₹179 crore. More importantly, management executed rigorous, sweeping cost-control measures. Consultant fees were slashed by 57%, and the massive marketing costs were curtailed by 24% (down to ₹69 crore). Consequently, MakeO successfully trimmed its net losses by 32% to ₹150 crore. Provisional data for FY25 projects a slight revenue contraction to ₹161 crore alongside a further narrowed net loss of ₹91.6 crore.
| Financial Metric | FY22 | FY23 | FY24 | FY25 (Projected) |
| Operating Revenue | ₹78.45 Cr | ₹168.0 Cr | ₹179.0 Cr | ₹161.0 Cr |
| Total Expenses | ₹263.4 Cr | ₹395.0 Cr | ₹332.0 Cr | ₹318.0 Cr |
| Net Loss | ₹184.29 Cr | ₹220.0 Cr | ₹150.0 Cr | ₹91.6 Cr |
| EBITDA Margin | -217.0% | -115.4% | -66.12% | N/A |
| Expense to Earn ₹1 | ₹3.36 | ₹2.35 | ₹1.85 | N/A |
Data synthesized from statutory filings and TheKredible intelligence reports.
The fundamental insight derived from these financials is the steady improvement in unit economics. In FY22, MakeO spent an unsustainable ₹3.36 to earn a single rupee of revenue; by FY24, this ratio improved significantly to ₹1.85. While absolute profitability remains elusive, the trajectory indicates that the massive fixed costs of the manufacturing facility and technological infrastructure are beginning to achieve operating leverage.
Capitalization, Funding History, and Valuation Dynamics
MakeO’s capitalization history perfectly mirrors the macroeconomic exuberance of the 2020-2022 tech boom and the subsequent “funding winter” that mandated severe valuation corrections across the global startup ecosystem.
To date, the company has raised over $100 million across multiple equity and venture debt rounds.
- Series A (Jan 2021): Raised $5 million led by Think Investments, establishing the initial proof of concept.
- Series B (Aug 2021): Raised $20 million led by Eight Roads Ventures.
- Series C (May 2022): Raised $40 million led by Eight Roads, Paramark, and IIFL, which provided the capital to accelerate regional expansion and officially launch the Skinnsi vertical.
- 2024 Extension: In January 2024, the company secured a highly publicized $16 million (₹135 crore) led by 360 ONE Asset and Ashish Kacholia, achieving a peak paper valuation of approximately $265 million (₹2,231 crore).
In a stark reflection of the shifting venture capital landscape, regulatory filings in May 2025 revealed that MakeO initiated a fresh funding round to raise ₹100 crore (approximately $12 million), closing an initial tranche of ₹54.7 crore ($6.43 million). The round was led by internal stakeholders, including Siddharth Shah, Mahendra Shah, and 360 ONE.
Crucially, the compulsorily convertible preference shares (CCPS) were issued at ₹943.7 each, representing a severe 57% valuation cut (a “downround”), bringing the company’s post-money valuation down to $124 million (₹1,055 crore). This downround should not be interpreted strictly as a localized failure of MakeO’s business model. Rather, it reflects a broader ecosystem recalibration where growth-stage health-tech companies are being aggressively repriced based on immediate cash flow and EBITDA potential rather than distant, speculative TAM projections. By accepting the dilution to raise internal capital, the founders astutely prioritized balance sheet survival and M&A liquidity over preserving vanity valuation metrics.
Risks and Challenges: The Ghost of SmileDirectClub
The most existential strategic threat to MakeO is avoiding the catastrophic fate of SmileDirectClub (SDC). Once valued at $8.9 billion, the US-based pioneer of D2C aligners filed for Chapter 11 bankruptcy in late 2023, suffocating under $900 million in debt and ceasing operations entirely, leaving thousands of patients stranded mid-treatment.
SDC failed due to three fatal structural errors. First, it completely alienated the clinical orthodontic community, leading to brutal regulatory warfare and lawsuits from dental boards across the United States. Second, its absolute reliance on a remote, doctor-less model meant it failed to manage complex clinical complications, leading to severe patient injuries (e.g., tooth loss, nerve damage) and subsequent class-action lawsuits. Third, the customer acquisition costs required to sustain high volumes in a purely D2C model fundamentally eroded its pricing advantage.
MakeO management has clearly observed this collapse and actively diverted its strategy. By deeply embedding over 100 in-house orthodontists into its workflow, expanding its physical clinic footprint, partnering with 2,200 external dentists, and diversifying into aesthetic dermatology to offset marketing costs, MakeO is actively engineering a clinical moat that SDC critically lacked. MakeO recognizes that in healthcare, vertical integration without vertical clinical expertise is a fatal trap.
Legal, Compliance, and Regulatory Hurdles
Despite its strategic pivots, MakeO navigates a highly precarious regulatory gray area. Dental care in India is strictly governed by the Dentists Act, 1948, and overseen by the Dental Council of India (DCI) and respective State Dental Councils.
The tension erupted in May 2024 when the DCI issued a severe public notice directly naming “Toothsi” (among others) for engaging in unauthorized dental practices. The Council alleged that conducting teeth scanning and delivering aligner services directly at patients’ homes by individuals not explicitly registered with the State Dental Councils constitutes a direct violation of the Dentists Act and the Revised Dentists (Code of Ethics) Regulations, 2014. The DCI ordered state tribunals to issue immediate “Cease and Desist” orders against these companies and to initiate legal action, citing severe risks to patient safety. Toothsi Business Model: Transforming Orthodontic Care Through Digital Innovation.
This regulatory hostility explains MakeO’s urgent strategic pivot into acquiring physical clinics (like Apple Dental) and forging partnerships with registered practitioners. By ensuring that a registered orthodontist approves every single virtual smile plan, and by shifting the initial scanning process to registered partner clinics, MakeO aims to transition from a legally vulnerable “pure remote” model to a fully compliant “doctor-directed” hybrid model. Additionally, legal precedents exist where the Delhi High Court has stayed overreaching DCI orders (e.g., arbitrarily cancelling admissions without natural justice), indicating that statutory bodies face judicial checks. This provides MakeO with critical legal breathing room to adjust its operational footprint while defending its business model in court.
Sustainability and ESG Considerations
As clear aligner therapy scales exponentially, the environmental impact of thermoplastic waste has emerged as a critical Environmental, Social, and Governance (ESG) concern for the dental industry. MakeO’s aligners are manufactured using durable thermoplastic polymers, specifically Polyurethane (PU) and Polyethylene Terephthalate Glycol (PETG).
Because clear aligners are exposed to saliva, blood, and oral biofilms for weeks, used aligners are classified as Class IIa biomedical waste. They cannot be routinely recycled in municipal streams or safely incinerated, as they release toxic, carcinogenic byproducts like dioxins. An average patient utilizes 20 to 40 sets of aligners, generating significant non-biodegradable plastic waste that persists in landfills for centuries.
While the broader scientific community is exploring advanced chemical recycling methods—such as alkaline hydrolysis to recover 4,4′-methylenedianiline (MDA) from plastics—and third-party recycling partnerships (like the TerraCycle initiative in the West), MakeO has yet to publicly outline a comprehensive closed-loop recycling program. Implementing a bio-hazardous “take-back” protocol at its 110+ experience centers, utilizing ozone-based sterilization before industrial recycling, would not only mitigate its environmental footprint but also serve as a powerful brand differentiator for environmentally conscious Gen-Z consumers.
Growth Strategy, M&A, and Future Plans
The most significant strategic inflection points in MakeO’s history occurred consecutively between late 2025 and early 2026, marking a definitive shift from organic domestic growth to aggressive, inorganic regional consolidation.
The Offline Pivot: Apple Dental Acquisition
In August 2025, MakeO acquired a 100% equity stake in Apple Oral and Dental Pvt. Ltd. (Apple Dental) for ₹10.98 crore in a mix of cash and stock, alongside extending a ₹1.5 crore loan. Apple Dental operated a highly profitable chain of 20 physical dental clinics across Andhra Pradesh and Telangana.
The strategic rationale is clear: MakeO’s premium pricing faced a demand ceiling in highly saturated metro markets. Expanding into Tier-2 and Tier-3 cities organically is notoriously expensive and slow due to localized brand trust deficits. Acquiring an established regional chain provides immediate physical infrastructure, local clinical trust, and a captive patient base to seamlessly cross-sell Toothsi aligners and Skinnsi treatments, pivoting MakeO deeply into the offline clinical realm required to appease regulators.
Regional Dominance: The Zenyum Merger
In February 2026, MakeO executed a landmark transaction by acquiring Zenyum, a highly successful Singapore-based consumer dental company backed by Peak XV, L Catterton, and RTP Global. Framed publicly as a “merger of equals” due to their similar revenue scales, the legal and financial structure definitively positions Zenyum as a subsidiary operating under MakeO’s Indian holding company, with MakeO’s CEO Dr. Arpi Mehta leading the joint entity.
This merger radically alters the Asian dental landscape:
- Massive Geographic Footprint: The combined entity now operates across 10 distinct jurisdictions, including India, Singapore, Malaysia, Vietnam, Japan, Taiwan, Hong Kong, Saudi Arabia, Qatar, and the UAE.
- Supply Chain Consolidation: The cornerstone of the deal is manufacturing centralization. MakeO’s ISO-certified, FDA-cleared facility in Mumbai will serve as the global manufacturing engine for Zenyum’s entire Asian distribution network. This dramatically increases capacity utilization, drastically lowering the per-unit cost of aligner production.
- Path to Profitability: The post-merger entity commands a combined revenue exceeding ₹500 crore ($55.1 million) and boasts a network of over 1,100 partner dentists. Management anticipates this combined scale and supply-chain efficiency will push the entire group into absolute profitability within two quarters, establishing a robust foundation for a potential Initial Public Offering (IPO) in the coming years.
Strategic SWOT Analysis
| Strategic Domain | Key Elements and Observations |
| Strengths | – Vertical Integration: End-to-end control of 3D scanning, AI planning, and TPU manufacturing preserves high margins and ensures quality control. – Omnichannel Network: 110+ physical centers and 2,000+ clinical partners build localized trust and satisfy regulatory demands for physical oversight. – Clinical Legitimacy: Founded and directed by experienced orthodontists, preventing the clinical failures seen in purely tech-driven peers. – Pan-Asian Scale: The Zenyum merger creates massive supply chain efficiencies and market access across 10 nations. |
| Weaknesses | – Fragile Unit Economics: Despite recent improvements, high marketing and consultant costs have historically kept the firm in deep net losses. – Corporate Culture: High employee dissatisfaction, reports of toxic management, and severe attrition hinder long-term talent retention. – High Fixed Costs: Maintaining a massive 20,000 sq ft manufacturing facility requires continuous, high-volume throughput to remain viable. |
| Opportunities | – Tier 2/3 Expansion: M&A activity (Apple Dental) allows rapid penetration into previously inaccessible, high-growth Indian demographics. – Economies of Scale: Acting as the manufacturing hub for Zenyum’s vast Asian network will rapidly accelerate the path to EBITDA profitability. – Adult Orthodontics Shift: The destigmatization of adult braces provides a compounding, expanding TAM globally. |
| Threats | – Regulatory Scrutiny: Active, formalized hostility from the Dental Council of India regarding at-home dental scans poses an existential legal threat. – Price Compression: Budget homegrown aligner brands (e.g., Snazzy, 32 Watts) threaten to undercut Toothsi’s mid-market pricing advantage. – Macro Environment: Capital scarcity in the venture market penalizes cash-burning models, as evidenced by the severe 2025 downround. |
Final Evaluation and Strategic Outlook
MakeO Healthcare Technologies represents a definitive case study in the maturation of the Indian health-tech ecosystem. The company successfully executed the first phase of its lifecycle: identifying a massive consumer surplus in adult orthodontics, leveraging deep clinical expertise to build a viable, FDA-cleared product (Toothsi), and utilizing aggressive venture capital to blitz-scale brand awareness across the subcontinent.
However, the era of easy victories driven by pure D2C arbitrage is decisively over. The severe valuation downround in their 2025 funding cycle reflects a mature market that demands immediate operational profitability over distant top-line vanity metrics. Management’s response to this harsh reality has been exceptionally strategic and unsentimental. By absorbing Apple Dental, they grounded the brand in the offline, clinical reality required by Indian healthcare consumers and regulators. By acquiring Zenyum in a masterstroke of regional consolidation, they instantly expanded their TAM across ten nations and secured the raw volume throughput necessary to make their massive Mumbai 3D-printing facility immensely profitable.
The primary existential threats to MakeO are no longer technological or competitive; they are regulatory and cultural. To secure its future—and a potential IPO by 2028—MakeO must proactively collaborate with the Dental Council of India to establish safe, regulated parameters for teledentistry, ensuring they do not suffer the legal death-by-a-thousand-cuts that ultimately bankrupted SmileDirectClub. Simultaneously, the executive team must radically overhaul its internal corporate culture to stem clinical attrition; exceptional healthcare cannot be delivered by a disenfranchised workforce. If MakeO can stabilize its human capital and successfully navigate the regulatory labyrinth, its vertically integrated, pan-Asian platform is uniquely positioned to dominate the future of clinical aesthetics and digital dentistry across the Eastern Hemisphere. Toothsi Business Model: Transforming Orthodontic Care Through Digital Innovation.
